Harvard Bioscience (HBIO) Non-Current Deferred Tax Liability (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Non-Current Deferred Tax Liability data on file, last reported at $313000.0 in Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 56.35% year-over-year to $313000.0 in Q1 2026; TTM through Mar 2026 was $313000.0, a 56.35% decrease from a year earlier, with the FY2025 full-year figure at $317000.0, down 55.35% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $313000.0, down from $317000.0 in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for HBIO reached as high as $2.4 million in Q2 2022 and fell as low as $313000.0 in Q1 2026.
• Historically, Non-Current Deferred Tax Liability has averaged $826882.4 across 5 years, with a median of $717000.0 in 2025.
• Across the five-year window, Non-Current Deferred Tax Liability surged 54.39% in 2022 and sank 72.52% in 2023, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $590000.0 in 2022, then jumped by 31.53% to $776000.0 in 2023, then dropped by 8.51% to $710000.0 in 2024, then sank by 55.35% to $317000.0 in 2025, then dropped by 1.26% to $313000.0 in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $313000.0 in Q1 2026, $317000.0 in Q4 2025, and $733000.0 in Q3 2025.